Genmab’s Epcoritamab-R-ICE Combo Shows 87% Response Rate in High-Risk Relapsed DLBCL Patients Eligible for Stem Cell Transplant

Genmab A/S announced new results from the Phase 1b/2 EPCORE® NHL-2 trial Arm 10 (NCT04663347), evaluating epcoritamab, a T-cell engaging bispeci...

June 16, 2025 | Monday | News
QIAGEN and Incyte Partner to Develop Global Companion Diagnostic Panel for CALR-Mutant Blood Cancers

QIAGEN N.V.  and Incyte  announced a new global collaboration to develop a novel diagnostic panel to support Incyte’s extensive portfolio...

June 16, 2025 | Monday | News
Chiesi Group and Key2Brain Expand Collaboration to Advance BBB-Crossing Therapies for Ultra-Rare Lysosomal Storage Disorders

Collaboration will leverage Key2Brain’s technology to develop blood-brain barrier-crossing enzyme replacement therapies for lysosomal storage disor...

June 12, 2025 | Thursday | News
Persica Secures EU Patent for PP353 Targeting Chronic Low Back Pain

Persica Pharmaceuticals Limited (Persica), a clinical stage biotechnology company developing a transformative treatment for chronic Low Back Pain (cLBP),...

June 12, 2025 | Thursday | News
XL-protein and Grifols Partner to Develop Novel Long-Acting Biopharmaceutical Using PASylation® Technology

XL-protein GmbH, a pioneer in the area of biopolymers for pharmacokinetic optimization, announced  that it has entered into a worldwide License, Dev...

June 11, 2025 | Wednesday | News
SynaptixBio Advances First Clinical Candidate for Rare H-ABC Disease With Promising Antisense Oligonucleotide Therapy

SynaptixBio, the only company licensed to commercialise a treatment for a rare, deadly disease, says the drug could halt disease progression and even rever...

June 11, 2025 | Wednesday | News
OBI Pharma and TegMine Therapeutics Enter ADC Collaboration to Target Cancer-Specific Glycans

OBI Pharma, Inc. (OBI), a clinical-stage global oncology company specialized in the development of novel cancer therapies such as antibody-drug conjugate...

June 10, 2025 | Tuesday | News
SOLVE FSHD and Modalis Partner to Advance CRISPR-Based Epigenome Editing Therapy for Muscular Dystrophy

-SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Ther...

June 09, 2025 | Monday | News
Samsung Bioepis Partners with NIPRO to Advance Biosimilars in Japan

Samsung Bioepis Co., Ltd. (“Samsung Bioepis”) announced that the company has entered into a license, development and commercialization agreem...

June 09, 2025 | Monday | News
AstriVax Begins Clinical Trial for AVX70371, a Potential Functional Cure for Chronic Hepatitis B

Third asset to advance into clinical trials, validating broad potential of Launch-iT platform All subjects treated with first dose of AVX70371 Launch-...

June 06, 2025 | Friday | News
Agenus and Zydus Forge Strategic Partnership to Advance BOT/BAL Immunotherapy and Launch BioCDMO Operations in the U.S.

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced it has signed definitive partnership agreements with Zydus Lifescienc...

June 05, 2025 | Thursday | News
Biocytogen and NJCTTQ Receive NMPA IND Approval for NTB003 to Treat Thyroid Eye Disease

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) and Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. (“NJC...

June 05, 2025 | Thursday | News
Acerand Therapeutics Doses First Patient in Phase I Trial of Novel CYP11A1 Inhibitor ACE-232 for Prostate Cancer

Acerand Therapeutics, a clinical-stage biotech company focusing on the discovery and development of innovative small-molecule therapies in oncology, toda...

June 05, 2025 | Thursday | News
Forging the Future of Biomanufacturing: How VVMF and Cytiva Are Elevating Australia’s Global Role

As the world recalibrates its life sciences infrastructure post-pandemic, Australia is stepping up as a regional powerhouse in biomanufacturing—espec...

June 05, 2025 | Thursday | Interaction

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close